Biotech | January 22, 2022
Lannett receives USFDA safety review for biosimilar insulin glargine
Go-ahead for pivotal clinical trial which is expected to commence by March
Go-ahead for pivotal clinical trial which is expected to commence by March
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Biocon has reported consolidated financial results for the period ended December 31, 2021
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Narayanan to lead SeQuent through next phase of consolidation and growth
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
